Walter Brendel Centre of Experimental Medicine, Ludwig Maximilians University, Munich, Germany.
Am J Physiol Heart Circ Physiol. 2012 Aug 15;303(4):H429-38. doi: 10.1152/ajpheart.00934.2011. Epub 2012 Jun 15.
The cytokine midkine (MK) promotes tumor growth mainly by inducing angiogenesis. Here, we identified the source of MK in the vascular system under hypoxic conditions and demonstrated the relevance of MK during ischemia of normal tissue. Hypoxia increased MK protein expression in human polymorphonuclear neutrophils (PMN), monocytes, and human umbilical vein endothelial cells (HUVEC) compared with normoxia. Immunoelectron microscopy showed elevated cell surface expression of MK in PMN and monocytes during hypoxia. However, only HUVEC released significant amounts of soluble MK during hypoxia compared with normoxia (301 ± 81 pg/ml vs. 158 ± 45 pg/ml; P < 0.05). Exogenous MK induced neovascularization in a chorioallantoic membrane (CAM) assay compared with negative control as measured by counting the number of branching points per visual field (1,074 ± 54 vs. 211 ± 70; P < 0.05). In a hind limb ischemia model, the angiogenic response was almost completely absent in MK-deficient mice, whereas control animals showed a profound angiogenic response measured as proliferating endothelial cells per visual field (45 ± 30 vs. 169 ± 34; P < 0.01). These unanticipated results identified endothelial cells as the source of soluble MK in the vascular system during hypoxia and defined MK as a pivotal player of angiogenesis during ischemia in nonmalignant tissue.
细胞因子中期因子 (MK) 主要通过诱导血管生成来促进肿瘤生长。在这里,我们确定了缺氧条件下血管系统中 MK 的来源,并证明了 MK 在正常组织缺血期间的相关性。与常氧相比,缺氧增加了人多形核粒细胞 (PMN)、单核细胞和人脐静脉内皮细胞 (HUVEC) 中的 MK 蛋白表达。免疫电子显微镜显示,在缺氧期间,PMN 和单核细胞中 MK 的细胞表面表达增加。然而,与常氧相比,只有 HUVEC 在缺氧期间释放大量可溶性 MK(301 ± 81 pg/ml 对 158 ± 45 pg/ml;P < 0.05)。与阴性对照相比,外源性 MK 在鸡胚尿囊膜 (CAM) 测定中诱导了新血管生成,通过计数每个视野的分支点数量来衡量(1074 ± 54 对 211 ± 70;P < 0.05)。在下肢缺血模型中,MK 缺陷小鼠的血管生成反应几乎完全缺失,而对照动物的血管生成反应表现为每个视野的增殖内皮细胞(45 ± 30 对 169 ± 34;P < 0.01)。这些意外的结果确定了缺氧条件下血管系统中可溶性 MK 的内皮细胞来源,并将 MK 定义为非恶性组织缺血期间血管生成的关键参与者。